AstraZeneca signs for Verdion’s Södertälje logistics park

Verdion has secured global pharmaceutical company AstraZeneca as the newest tenant for Verdion Park Södertälje, south of Stockholm.

The new 31,546 sq m development is located in the city’s eastern submarket, Gärtuna, less than ten minutes from the E20 motorway and 15 minutes from Södertälje Port. Verdion is targeting a BREEAM Excellent sustainability rating for the facility.

AstraZeneca’s largest production facility is located in Södertälje, where it produces more than one third of the company’s global sales value. Exports from AstraZeneca in Södertälje represent 68 % of Sweden’s total pharmaceutical exports and 5 % of the country’s total goods exports. At its adjacent site in the Gärtuna area, 11 to 12 billion tablets and capsules are manufactured annually for more than 100 markets.

AstraZeneca has leased 14,852 sq m of space at Verdion Park Södertälje, to be used as inbound ambient and cold-chain warehousing, supplying its neighbouring production facilities.

This achievement marks the second lease agreement at the park in a short period of time, with AstraZeneca joining the leading Swedish green energy company Söderenergi, which signed for the adjacent DC1.1 unit in May this year.

With three quarters of the asset now leased, Verdion is now marketing the final unit, DC1.2, which offers 8,801 sq m in total, including 7,876 sq m of warehousing and a 925 sq m mezzanine.

Fredrik Salman, Investment Director at Verdion, said: “We are committed to working closely with occupiers to ensure that new logistics assets effectively meet operational requirements as well as providing high levels of sustainability and speed of delivery. Securing this major global business for the park is testament to the quality of our vertically integrated approach, from acquisition and concept through to leasing and completion.”

Simon Davies, Senior Technical Development Manager at Verdion, added: “Close cooperation and collaboration with AstraZeneca was key to unlocking the redevelopment of this complex and challenging brownfield site and has continued throughout the construction process.

“In late 2024, as AstraZeneca’s needs became known, Verdion took a strategic decision to prepare the building for cold-chain, storage of pharmaceutical products and automation. It is fantastic to see this commitment pay off.”